Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.…
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics (NASDAQ: RAPP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 84 employees.
The shares were at 23.16 USD on 20 November 2026, down 8.7% over 52 weeks. Its 52-week range is 22.06 USD to 52.83 USD: the price is 56.2% below the high and 5.0% above the low.
Its market capitalisation is 1.37B USD.
Rapport Therapeutics reports return on equity of -23.0%.
It holds more cash than debt, a net cash position of 385.64M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 14 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 64.21 USD is 177.3% above the current price. The next earnings report is expected on 9 March 2027.